
Pancreatic Ductal Adenocarcinoma (PDAC)
Description
MarketVue®: Pancreatic Ductal Adenocarcinoma (PDAC)
The MarketVue®: Pancreatic Ductal Adenocarcinoma (PDAC) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Pancreatic Ductal Adenocarcinoma report is supported by 7 qualitative interviews with key opinion leaders, a quantitative survey with 23 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• Novartis
• Pancreatic Cancer Action Network
• Panbela Therapeutics
• BioLineRx
• Astellas Pharma
• TME Pharma
• Merck Sharp & Dohme
• SynerGene Therapeutics
• Ability Pharma
• AstraZeneca
• ERYTECH
• Cornerstone Pharmaceuticals
• Eli Lilly
• Pharmacyclics
• Halozyme Therapeutics
• Sumitomo Pharma
• FibroGen
Key drugs mentioned:
• Capecitabine
• FOLFIRINOX
• Gemcitabine
• Cisplatin
• Olaparib (Lynparza)
• Larotrectinib (Vitrakvi)
• Entrectinib (Rozlytrek)
• Pembrolizumab (Keytruda)
• Pamrevlumab
• Canakinumab (Ilaris)
• Spartalizumab
• SM-88
• Ivospemin
• Motixafortide
• Zolbetuximab
• Olaptesed pegol
• SGT-53
• ABTL0812
• Selumetinib (Koselugo)
• Durvalumab (Imfinzi)
• Paclitaxel (Abraxane)
• Eryaspase
• Devimistat
• Pegilodecakin
• Ibrutinib (Imbruvica)
• PEGPH20
• Napabucasin
Please note: the online download version of this report is for a global site license.
Table of Contents
33 Pages
- 1. DISEASE OVERVIEW
- An aggressive, lethal cancer beginning in the ducts of the pancreas
- Figure 1.1. Signs and symptoms of PDAC
- Table 1.1. Risk factors associated with PDAC
- PDAC is a lethal cancer with limited treatments but many potentially actionable targets
- Table 1.2. Staging of disease in PDAC
- Table 1.3. Five-year survival rates for pancreatic cancer
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Table 2.1. Incident populations of PDAC in the US, EU4 and UK
- Drug-treated PDAC patients
- Table 2.2. Drug-eligible and drug-treated PDAC patients by stage
- 3. DIAGNOSIS AND CURRENT TREATMENT
- Diagnosis overview
- Figure 3.1. Oncologist-reported PDAC patient segmentation
- Diagnostic journey of PDAC patients – timely diagnosis is challenging due to the nature of the symptoms
- Treatment flows for resectable and borderline resectable patients
- Table 3.1. Surgery-eligible PDAC patient segments
- Treatment of resectable and borderline resectable PDAC
- Figure 3.2. Neoadjuvant therapy use prior to surgery in surgery-eligible PDAC patients
- Figure 3.3. Adjuvant therapy in patients who have undergone resection
- Physician insights on drug treatment in surgery-eligible patients
- Treatment of locally advanced and metastatic patients
- Table 3.2. Unresectable PDAC patient segments
- Treatment of metastatic patients
- Figure 3.4. Percentage of oncologists who prescribe Olaparib to BRCA+ patients as a maintenance tx
- FOLFIRNIOX and gemcitabine-based therapies are the backbone of PDAC treatment
- Figure 3.5. Oncologist-reported current treatment share for locally advanced and metastatic patients: 1st-line setting
- Figure 3.6. Oncologist-reported current treatment share for locally advanced and metastatic patients: 2nd-line setting
- Identification of druggable targets guides treatment decisions in unresectable patients
- Table 3.3. Genetic and somatic testing of PDAC patients
- Figure 3.7. Oncologist-reported percentage of PDAC patients tested for germline and somatic mutations
- Key treatment dynamics that shape disease management and drug use in PDAC
- Table 3.4. Must-know PDAC treatment dynamics for now and the future
- PDAC market evolution
- Figure 3.8. Important dynamics of PDAC market evolution
- 4. UNMET NEED
- Overview
- Figure 4.1. Top unmet needs in PDAC
- Figure 4.2. Medical Oncologist unmet needs in PDAC
- Unmet needs – Physician perspectives
- Clinical outcomes that impact prescribing habits – Physician perspectives
- Figure 4.3. Importance of clinical outcomes on prescribing habits in 1st and 2nd line mPDAC
- 5. PIPELINE ANALYSIS
- Overview
- Figure 5.1. Percentage of oncologists rating target as “promising” for PDAC
- Physician commentary on emerging therapy targets
- Late-stage clinical development for metastatic PDAC
- Table 5.1. Comparison of selected late-stage trials in metastatic PDAC
- Early-stage clinical development for metastatic PDAC
- Table 5.2. Selected ongoing Phase 2 clinical trials
- Early-stage clinical development for metastatic PDAC (continued)
- Table 5.2. Selected ongoing Phase 2 clinical trials (continued)
- Novel therapy trial failure in PDAC and a new approach to trial design
- Table 5.3. Focus on the Phase 3 CanStem111P study of napabucasin
- 6. VALUE & ACCESS
- Overview
- Table 6.1. Current therapy pricing, US 2022
- Figure 6.1. Reimbursement and Access considerations for emerging therapies in PDAC
- 7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
- Appendix: List of abbreviations used in PDAC report
- Appendix: List of abbreviations used in PDAC report (continued)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.